• On 10 March 2022, the Food and Drug Administration (FDA) issued authorization (amended on 20 June 2022) granting Pfizer, Inc. the emergency use approval of Nirmatrelvir + Ritonavir (Paxlovid).

 Product Information

                     Patient Information Leaflet

• For more information on reporting side effects, click here.